Home » Stocks » FATE

Fate Therapeutics, Inc. (FATE)

Stock Price: $57.13 USD 1.86 (3.37%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $57.25 +0.12 (0.21%) Nov 25, 6:45 PM

Stock Price Chart

Key Info

Market Cap 4.98B
Revenue (ttm) 18.34M
Net Income (ttm) -148.58M
Shares Out 87.24M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $57.13
Previous Close $55.27
Change ($) 1.86
Change (%) 3.37%
Day's Open 55.27
Day's Range 54.61 - 57.15
Day's Volume 568,348
52-Week Range 13.26 - 57.15

More Stats

Market Cap 4.98B
Enterprise Value 4.57B
Earnings Date (est) Mar 8, 2021
Ex-Dividend Date n/a
Shares Outstanding 87.24M
Float 81.38M
EPS (basic) -1.85
EPS (diluted) -1.87
FCF / Share -0.57
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14.35M
Short Ratio 16.56
Short % of Float 17.63%
Beta 1.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 271.77
PB Ratio 10.82
Revenue 18.34M
Operating Income -123.76M
Net Income -148.58M
Free Cash Flow -49.35M
Net Cash 418.55M
Net Cash / Share 4.80
Gross Margin -420.34%
Operating Margin -674.83%
Profit Margin -810.10%
FCF Margin -269.08%
ROA -16.00%
ROE -42.92%
ROIC -58.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (14)

Buy 12
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$54.36*
(-4.85% downside)
Low
30.0
Current: $57.13
High
71.0
Target: 54.36
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue10.684.744.114.402.43-0.972.671.17
Revenue Growth125.32%15.44%-6.72%81.08%---63.63%128.21%-
Gross Profit10.684.744.114.402.43-0.972.671.17
Operating Income-101-67.09-42.13-31.96-27.78-24.90-17.68-13.56-13.29
Net Income-98.15-66.60-42.95-33.46-29.99-25.88-20.89-14.24-13.43
Shares Outstanding68.1956.2041.9831.7525.4820.455.901.090.83
Earnings Per Share-1.44-1.19-1.02-1.05-1.18-1.27-3.54-13.06-16.16
Operating Cash Flow-83.18-38.65-36.82-29.82-18.40-22.42-15.37-13.27-12.15
Capital Expenditures-7.40-2.30-1.73-0.44-1.50-0.88-0.24-0.710.20
Free Cash Flow-90.57-40.95-38.54-30.26-19.90-23.30-15.61-13.98-11.95
Cash & Equivalents22220110192.2364.9349.2254.169.216.51
Total Debt26.9314.8814.8110.6918.2419.611.733.674.84
Net Cash / Debt19518686.2681.5546.6929.6252.435.541.67
Assets30221310595.0567.9651.1855.5811.087.85
Liabilities57.5252.5628.1021.8929.9222.844.7463.9058.54
Book Value24516077.1973.1538.0428.3450.85-52.83-50.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fate Therapeutics, Inc.
Country United States
Employees 178
CEO J. Scott Wolchko

Stock Information

Ticker Symbol FATE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FATE
IPO Date October 1, 2013

Description

Fate Therapeutics, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.